The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy (CART19-BE-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03144583
Recruitment Status : Completed
First Posted : May 9, 2017
Last Update Posted : August 28, 2023
Sponsor:
Collaborator:
Instituto de Salud Carlos III
Information provided by (Responsible Party):
Sara V. Latorre, Institut d'Investigacions Biomèdiques August Pi i Sunyer

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To assess the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity [A3B1] conjugated with the co-stimulatory regions 4-1BB and CD3z ) safety on patients with leukemia or lymphoma CD19+ resistant or refractory to treatment and with a prognosis of less than 2 years.

Condition or disease Intervention/treatment Phase
Leukemia Lymphoma Biological: Adult differentiated autologous T-cells Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description: Open label
Primary Purpose: Other
Official Title: Pilot Study on the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity Conjugated With the Co-stimulatory Regions 4-1BB and CD3z in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
Actual Study Start Date : June 15, 2017
Actual Primary Completion Date : September 13, 2022
Actual Study Completion Date : September 13, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia Lymphoma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Adult differentiated autologous T-cells
Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z. Such cells will be administered in a single infusion intravenously at a total ARI-0001 cell dose of 0.5-10 x 106 / kg body weight.
 Biological: Adult differentiated autologous T-cells
After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Procedure-related mortality (PRM) [ Time Frame: Year 1 ]
    Any death not caused directly by leukemia / lymphoma. For the estimation of PRM, relapse or progression of the disease will be considered as a competitive event.

  2. Procedure-related mortality (PRM) [ Time Frame: Year 3 ]
    Any death not caused directly by leukemia / lymphoma. For the estimation of PRM, relapse or progression of the disease will be considered as a competitive event.

  3. Assessment of toxicity [ Time Frame: Month 3 ]
    number of adverse events grade III-IV using CTC (common toxicity criteria)

  4. Assessment of toxicity [ Time Frame: Year 1 ]
    number of adverse events grade III-IV using CTC (common toxicity criteria)


Secondary Outcome Measures :
  1. Response rate (overall and complete) [ Time Frame: Month 3 and Year 1 ]

    Defined differently for each disease:

    • On chronic lymphoid and acute lymphocytic leukemia, the usual criteria NCCN and IWCLL will be used.
    • On non-Hodgkin's lymphoma, the Lugano criteria will be used-
    • On patients with leukemia will be quantified the persistence of minimal residual disease, in bone marrow and peripheral blood, using multiparametric cytometry and new generation sequencing techniques.

  2. Progression-free survival [ Time Frame: Year 2 after procedure ]
    Time lag between infusion of ARI-0001 and the progression of disease or death. Patients alive and in complete remission will be censored at the last follow-up

  3. Overall survival (OS) at 2 years [ Time Frame: 3 years ]
    Time lag between the infusion of ARI-0001 and the death of the patient from any cause. Living patients will be censored at the the last follow-up.

  4. In vivo survival of ARI-0001 cells in peripheral blood, bone marrow and cerebrospinal fluid [ Time Frame: months 1,2,3,4,5,6 ]
    Determined monthly during the first 6 months by flow cytometry and quantitative transgene PCR.

  5. In vivo survival of ARI-0001 cells in peripheral blood, bone marrow and cerebrospinal fluid [ Time Frame: months 9,12,15,18,21,24 ]
    Determined quarterly from month 6 until the 2 years after infusion, by flow cytometry and quantitative transgene PCR.

  6. Quality of life of included patients [ Time Frame: Month 3, 6, 12 ]
    Evaluated by a questionnaire completed by patients or their legal guardians

  7. Toxicity assessment [ Time Frame: Month 3 and year 1 ]
    defined as number of adverse events of any type occurring throughout the study using the common toxicity criteria


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of leukemia or CD19 + lymphoma, with a life expectancy less than 2 years that meet the following conditions:- Adult acute lymphoid leukemia in second or third response, not candidate for transplantation due to age, associated diseases or lack of donor, or in relapse post allogeneic transplant.- Pediatric acute lymphoid leukemia in second or third response, refractory or non-transplant candidate due to donor absence, or in relapse post allogeneic transplant, or with minimal residual residual disease (0.1% or greater) after two or more lines of treatment. - Symptomatic follicular lymphoma, which has received at least 2 treatment regimens (one of them including rituximab) and a progression-free interval of less than 2 years. Patients not candidates for transplantation or post-transplant relapse may be included.- Symptomatic chronic lymphocytic leukemia, which has received at least 2 treatment regimens (one of them including rituximab) and a progression-free survival of less than 2 years. Patients with a 17p deletion or TP53 mutation may be included after the first line of treatment. - Mantle cell lymphoma in the first relapse (or higher) when it is not a candidate for transplantation, or second post-transplant relapse (or higher). - Diffuse large cell lymphoma in first relapse (or higher) when it is not a candidate for transplantation, or second post-transplant relapse (or higher).
  • Age greater than 2 years and less than 80.
  • ECOG functional status from 0 to 2
  • Life expectancy of at least 3 months.
  • Appropriate venous access to perform an apheresis procedure. Absence of contraindications for it.
  • Signature of informed consent (patient or legal guardian).

Exclusion Criteria:

  • Treatment with any experimental or non-marketed substance within four weeks prior to recruitment, or actively participating in another therapeutic clinical trial.
  • Diagnosis of another past or present neoplasm. Patients may be included in complete remission for more than 3 years, or with a history of non-melanoma skin cancer or completely resected in-situ carcinoma.
  • Central nervous system involvement (CNS-3) at inclusion. Inclusion will be permitted with patients with a lower grade (CNS-2) or with CNS-3 who have responded to intrathecal chemotherapy.
  • Early relapse after allogeneic transplantation (less than 3 months for apheresis of mononuclear cells, less than 6 months for infusion of ARI-0001) or patients on active immunosuppressive therapy for graft-versus-host disease (corticosteroids or other systemic immunosuppressants ).
  • Active infection requiring systemic medical treatment such as chronic kidney infection, chronic lung infection or tuberculosis.
  • HIV infection.
  • Concurrent and uncontrolled medical illnesses including cardiac, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological or psychiatric diseases which in the opinion of the researcher represent a risk to the patient.
  • Positive serology for hepatitis B, defined as a positive test for HBsAg. In addition, if the patient is HBsAg negative but has anti-HBc antibodies it will be necessary to perform a DNA test of the hepatitis B virus, and if the result is positive the patient will be excluded.
  • Positive serology for hepatitis C, defined as a positive test for anti-HCV antibodies confirmed by RIBA.
  • Severe organ failure, defined as a cardiac ejection fraction <40%; DLCO <40%; calculated glomerular filtrate rate <30 ml / min; Or bilirubin> 3 times the upper limit of normal (unless it is due to CLL or Gilbert syndrome).
  • Pregnant or lactating women. Women of childbearing potential should have a negative pregnancy test in the screening phase.
  • Women of childbearing age, including those whose last menstrual cycle was in the year prior to screening, who are unable or unwilling to use highly effective contraceptive methods from the start of the study to the end of the study.
  • Men who are unable or unwilling to use highly effective contraceptive methods from the start of the study to the completion of the study.
  • The need to take glucocorticoids in a chronic manner at doses higher than 10 mg / day of prednisone (or equivalent) or other chronic immunosuppressants. Hormonal contraceptives, intrauterine device, intrauterine systems of hormonal release, sexual abstinence, vasectomy of the couple or bilateral tubal occlusion.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03144583


Locations
Layout table for location information
Spain
Hospital Clínic of Barcelona
Barcelona, Spain, 08036
Hospital Sant Joan de Deu
Barcelona, Spain, 08950
Sponsors and Collaborators
Sara V. Latorre
Instituto de Salud Carlos III
Investigators
Layout table for investigator information
Principal Investigator: Julio Delgado González, PhD MD Hospital Clinic of Barcelona
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Sara V. Latorre, Clinical Research Manager, Institut d'Investigacions Biomèdiques August Pi i Sunyer
ClinicalTrials.gov Identifier: NCT03144583    
Other Study ID Numbers: CART19-BE-01
First Posted: May 9, 2017    Key Record Dates
Last Update Posted: August 28, 2023
Last Verified: August 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sara V. Latorre, Institut d'Investigacions Biomèdiques August Pi i Sunyer:
CART19
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
 Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hematologic Diseases